FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review

by Vandana Singh, Benzinga Editor

February 17, 2021 10:00 AM | 1 min read | Make a Comment

The FDA has accepted for review Coherus BioSciences Inc's (NASDAQ: CHRS) marketing application for CHS-1420 and AbbVie's Inc (NYSE: ABBV) Humira (adalimumab) biosimilar product candidate, with action for December 2021.
If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2023.
The company says that annual U.S. Humira sales are projected to exceed $18 billion by the planned launch.
Humira is indicated for a range of diseases.
Price Action: CHRS shares are down 0.34% at $17.38 on last check Wednesday.